Zavante hits the finish line, declaring a pivotal win for its antibiotic now headed (eventually) to the FDA
The team at Zavante Therapeutics had a very simple goal.
Armed with $45 million in investor backing, they took a broad spectrum antibiotic that’s been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
